INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.77
-0.30 (-3.72%)
At close: Apr 3, 2025, 4:00 PM
7.74
-0.03 (-0.44%)
Pre-market: Apr 4, 2025, 4:05 AM EDT

Company Description

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.

It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs.

It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio, Inc.
INmune Bio logo
Country United States
Founded 2015
IPO Date Feb 4, 2019
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Raymond Tesi

Contact Details

Address:
225 NE Mizner Blvd., Suite 640
Boca Raton, Florida 33432
United States
Phone 858 964 3720
Website inmunebio.com

Stock Details

Ticker Symbol INMB
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $8.00
CIK Code 0001711754
CUSIP Number 45782T105
ISIN Number US45782T1051
Employer ID 47-5205835
SIC Code 2836

Key Executives

Name Position
Dr. Raymond Joseph Tesi M.D. Co-Founder, President, Chief Executive Officer, Chief Medical Officer and Chairman
David J. Moss M.B.A. Chief Financial Officer, Treasurer and Secretary
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer and Chief Manufacturing Officer
Joshua S. Schoonover Esq. General Counsel

Latest SEC Filings

Date Type Title
Apr 1, 2025 8-K Current Report
Mar 27, 2025 8-K Current Report
Mar 27, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Mar 7, 2025 424B5 Filing
Mar 4, 2025 8-K Current Report
Feb 12, 2025 8-K Current Report
Feb 10, 2025 8-K Current Report
Feb 10, 2025 8-K Current Report
Jan 28, 2025 8-K Current Report